ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 223

Clinical Predictors of Acute Gout Flares within Hospitalized Patients at a Tertiary Care Center in New York

Lara El Khoury1, Mohamad Yasmin1,2, Nabil Zeineddine1, Joseph Saabiye1, Saleha Riaz1, Sami Arnaout1, Talal El Imad1, Suzanne El-Sayegh3 and Rita Obeid4, 1Internal Medicine, Staten Island University Hospital, Northwell Health, Staten Island, NY, 2Infectious Diseases, Case Western Reserve University, Cleveland, OH, 3Internal Medicine, Program Director, Staten Island University Hospital, Northwell Health, Staten Island, NY, 4Psychology, The Graduate Center, CUNY, New York, NY

Meeting: 2016 ACR/ARHP Annual Meeting

Date of first publication: September 28, 2016

Keywords: Crystal-induced arthritis, Epidemiologic methods, gout, hyperuricemia and uric acid

  • Tweet
  • Email
  • Print
Session Information

Date: Sunday, November 13, 2016

Title: Metabolic and Crystal Arthropathies - Poster I: Clinical Practice

Session Type: ACR Poster Session A

Session Time: 9:00AM-11:00AM

Background/Purpose: Gout is the most prevalent inflammatory arthritis worldwide. Within the healthcare setting, gout flares contribute to substantial morbidity and complicated hospital stays. Identifying risk factors and preventing flares are mainstays of therapy. This case-case-control study aims at exploring the risk factors for developing an acute gout flare with special emphasis on inpatient stressors and gout attacks in the hospital setting.

Methods: This is a case-case-control study of all consecutive gout flares from January 2010 to January 2015. The first group of cases comprised patients who developed a gout exacerbation after 48 hours of admission to the hospital. The second group consisted of patients whose gout flare manifested within 48 hours of hospital admission. The control group included chronic gout patients that were hospitalized during the same time frame as cases but did not experience an acute gout attack during their stay. Two multivariable models were constructed, one including predictors of flare-up within hospitalized patients (>48 hrs), and the other including predictors for flare-up upon hospital admission (<48 hrs).

Results: A total of 530 patients were included in this study (184 gout cases >48 hrs of admission, 159 gout cases <48 hrs of admission, and 187 chronic gout controls). There were no significant differences in gender distribution, age means, length of stay, or Charlson comorbidity scores across all study groups. In the first multivariable model (gout attack>48 hrs of admission vs chronic gout controls), recent gastrointestinal bleeding (OR 3.0; CI 1.1-8.2), placement of a urinary catheter (OR 4.1; 95% CI 1.9-8.6), and antibiotic use >3 days (OR 3.2; 95% CI 1.4-7.5) constituted independent predictors of gout exacerbation within hospitalized patients. Subgroup antibiotic analysis revealed that inpatient gout exacerbations were associated with recent use of cephalosporins (p<0.001), quinolones (p=0.01), metronidazole (p=0.03), and vancomycin (p=0.001). In the second multivariable model, controls were more likely to have the following factors compared to cases: COPD (OR 1.89; 95% CI 1.1-3.3), rheumatoid arthritis (OR 4.2; 95% CI 1.2-15.3), recent infection (OR 2.2 95% CI 1.2-15.3), and a bedrest activity (OR 4.6 95% CI 1.7-12.6) order. In both models, Allopurinol (p<0.001) and Colchicine (p=0.003) use were significantly associated with chronic gout controls compared to cases.

Conclusion: Urinary catheter placement, antibiotic use, and gastrointestinal bleeding within 30 days seem to be unique predictors for gout flares within hospitalized patients. Prior use of cephalosporins (within 30 days) constituted an especially robust risk factor for an acute inpatient gout flare compared to controls. The design of this study permits for a more reliable assessment of inpatient risk factors compared to the classic case-control design.


Disclosure: L. El Khoury, None; M. Yasmin, None; N. Zeineddine, None; J. Saabiye, None; S. Riaz, None; S. Arnaout, None; T. El Imad, None; S. El-Sayegh, None; R. Obeid, None.

To cite this abstract in AMA style:

El Khoury L, Yasmin M, Zeineddine N, Saabiye J, Riaz S, Arnaout S, El Imad T, El-Sayegh S, Obeid R. Clinical Predictors of Acute Gout Flares within Hospitalized Patients at a Tertiary Care Center in New York [abstract]. Arthritis Rheumatol. 2016; 68 (suppl 10). https://acrabstracts.org/abstract/clinical-predictors-of-acute-gout-flares-within-hospitalized-patients-at-a-tertiary-care-center-in-new-york/. Accessed .
  • Tweet
  • Email
  • Print

« Back to 2016 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/clinical-predictors-of-acute-gout-flares-within-hospitalized-patients-at-a-tertiary-care-center-in-new-york/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology